Figure 1. Levels of TRECs and KRECs.

Levels of TRECs and KRECs in patient who developed PML (pmlMS; black dots), natalizumab-treated patients (nMS), untreated patients (uMS; white dots), and healthy donors (HD; white dots) were reported. The indicated time points (T0, T1, T2, T3, and T4) were those described in Table 1. In the pmlMS patient, whose four samples were analyzed at the time point T4, TRECs were always significantly lower (p<0.01) in comparison to nMS patients, uMS patients, and HD. The levels of TRECs of uMS patients and HD were also significantly different (p<0.01). KRECs of the pmlMS patient were lower (p<0.01) than those of nMS and HD at T0 and T4, lower than uMS at T0, and higher than those of uMS and HD at T1, T2 and T3. Horizontal lines indicate means and error bars indicate the 99% confidence intervals of the means, calculated after log transformation of the data.